MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bestatin trifluoroacetate

CAS No. : 223763-80-2

MCE 站：Bestatin trifluoroacetate

产品活性：Bestatin trifluoroacetate (Ubenimex trifluoroacetate) 是 CD13 (Aminopeptidase N)/APN 和 leukotriene A4 hydrolase 抑制剂，常用于癌症研究。

研究领域：Metabolic Enzyme/Protease  |  Anti-infection

作用靶点：Aminopeptidase  |  Bacterial  |  Antibiotic

In Vitro: Bestatin enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK in ATRA-sensitive APL NB4 cells. Bestatin can not reverse the differentiation block in ATRA-resistant APL MR2 cells. CD13 ligation with anti-CD13 antibody WM-15 results in phosphorylation of p38 MAPK, reduces the inhibition of Bestatin on the phosphorylation of p38 MAPK, and completely abolishes the enhancement of Bestatin on ATRA-inducing differentiation in NB4 cells. Bestatin (600 μM)-treated cells progress slower through the cell cycle due to decreased rate of cell growth and the frequency of cell division. Bestatin inhibits the frequency of mitosis and the inherent multinuclearity in D. discoideum, and is not cytotoxic to D. discoideum cells at 0-600 μM. Bestatin inhibits aminopeptidase activity in lysates of PsaA-GFP- and GFP-expressing cells by 69.39% ± 10.5% and 39.93% ± 18.7% of control, respectively.

In Vivo: Bestatin (20 μM) significantly reduces CD13 expression in diabetic mice and results a significant inhibition of MMP-9 specific gelationolytic band densities compared to diabetic vehicle-treated mice. Bestatin treatment significantly inhibits the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin treatment significantly downregulates the expression of both HIF-1α and VEGF in diabetic mice retinas. Furthermore, the upregulated expression of heparanase in diabetic mice retinas is significantly inhibited by intravitreal bestatin treatment. Bestatin (10, 1, and 0.1mg/kg, i.p.) treatment before the antigen-potentiated humoral response to SRBC results in an increased number of splenocytes producing hemolytic anti-SRBC antibodies (PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg) administered to mice five times on alternate days after cyclophosphamide injection does not change the suppressive effect of the drug regarding the number of PFC, and even causes the further decrease of the total anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation.

相关产品：Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Cycloheximide  |  Chloroquine  |  Staurosporine  |  Dexamethasone  |  Doxycycline (hyclate)  |  Actinomycin D  |  Cyclosporin A  |  G-418 disulfate  |  5-Azacytidine  |  Etoposide  |  Mitomycin C  |  CCCP  |  Nigericin sodium salt  |  Brefeldin A  |  Wortmannin  |  Resveratrol  |  Tunicamycin  |  Bleomycin sulfate  |  Hygromycin B  |  Tacrolimus  |  Ionomycin  |  Vancomycin hydrochloride  |  Streptozocin  |  Tanespimycin  |  Oligomycin A

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。